Forskning
Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital
Udgivet

Short-course vs long-course antibiotic treatment for community-acquired pneumonia: A literature review

Publikation: Bidrag til tidsskriftReviewForskningpeer review

DOI

  1. Drug-related challenges following primary total hip and knee arthroplasty

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Validation of registration of pharmacological treatment in the Danish Hip and Knee Arthroplasty Registers

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Camostat mesylate against SARS-CoV-2 and COVID-19-Rationale, dosing and safety

    Publikation: Bidrag til tidsskriftReviewForskningpeer review

Vis graf over relationer

BACKGROUND: It is well known that antibiotic use is the main driver for the increasing problems with resistant bacteria. Consequently, some countries have recommended shortening the duration of antibiotic treatment of community-acquired pneumonia (CAP). The aim of this study was to investigate whether the effectiveness of a short-course antibiotic is comparable to a longer course of antibiotics in adults with CAP and to assess whether the duration of an antibiotic course influences the development of resistant bacteria.

METHODS: A literature search was performed in PubMed and EMBASE. We included randomized, controlled trials (RCTs) comparing clinical success, microbiological efficacy, patient safety and antibiotic resistance in a short-course (5 days) vs a long-course antibiotic treatment (7+ days) for CAP.

RESULTS: Six RCTs were included. Clinical success rates were 87%-95% in patients treated with short-course antibiotics and 88%-94% in patients treated with a longer course. Eradication of pathogenic bacteria was found to be 100% and 95%-100% in patients treated with short-course and long-course antibiotics, respectively. No significant differences in adverse events were reported. However, none of the trials reported on the impact on the development of resistant bacteria.

CONCLUSION: Only few trials were included in this review and more RCTs are highly needed to be able to provide solid evidence for optimal treatment durations for patients diagnosed with CAP. Importantly, fluoroquinolones were often the drug of choice, and trials testing beta-lactam antibiotics, which are the type of antibiotics most often used in many European countries, should be aimed for in near future.

OriginalsprogEngelsk
TidsskriftBasic & clinical pharmacology & toxicology
Vol/bind124
Udgave nummer5
Sider (fra-til)550-559
Antal sider10
ISSN1742-7843
DOI
StatusUdgivet - maj 2019

Bibliografisk note

© 2019 Nordic Association for the Publication of BCPT (former Nordic Pharmacological Society).

ID: 59154883